Daniel P. Petrylak, MD, on Enfortumab Vedotin-ejfv as Monotherapy for Bladder Cancer

Posted: Tuesday, February 22, 2022

Daniel P. Petrylak, MD, of Yale Cancer Center, discusses his observations, based on recent study results, about the role of neoadjuvant single-agent therapy with enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer who are not eligible for cisplatin.